Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

// Kyle C. Strickland 1 , Brooke E. Howitt 1 , Sachet A. Shukla 2, 4 , Scott Rodig 1 , Lauren L. Ritterhouse 1 , Joyce F. Liu 3 , Judy E. Garber 4 , Dipanjan Chowdhury 5 , Catherine J. Wu 2, 4 , Alan D. D’Andrea 5 , Ursula A. Matulonis 3 , Panagiotis A. Konstantinopoulos 3 1 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 2 The Broad Institute of Harvard and MIT, Cambridge, MA, USA 3 Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 5 Division of Genomic Stability and DNA Repair, Dana Farber…

• UD
  U.S. Department of Defense

  Awards: W81XWH, W81XWH-10-1-0585
• OC
  Ovarian Cancer Research Fund

  Award: SU2C-AACR-DT16-15
• BS
  Bristol-Myers Squibb
• LA
  Leukemia and Lymphoma Society
• NO
  National Ovarian Cancer Coalition

  Award: SU2C-AACR-DT16-15
• BF
  Blavatnik Family Foundation
• NI
  National Institutes of Health

  Award: W81XWH
• SU
  Stand Up To Cancer

  Award: SU2C-AACR-DT16-15
• NC
  National Cancer Institute
• OC
  Ovarian Cancer Academy